FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3000049216> ?p ?o ?g. }

• W3000049216 abstract "ABSTRACT Background For prevention of emesis during anthracyline (A)/cyclophosphamide(CPA) therapy for breast cancer, use of aprepitant(AP) combined with serotonin receptor antagonist(5HT3) and dexamethasone(DEX) is recommended. AP, known to function as a CYP3A4 inhibitor, has been reported to interfere with metabolism of chemotherapeutic drugs. It has been also reported that AP does not influence the AUC's of 4-OH and DCE. Although, in the previous clinical reports for AC, the toxicities were not significant in patients who were given AP, compared to those　without AP, we have experienced a cases of severe hyponatremia probably related to AP. Thus, we investigated an impact of AP on Na metabolism during chemotherapy using CPA for breast cancer. Material and methods We investigated serum levels of Na in primary breast cancer patients who received CPA-combined therapy with the use of AP as anti-emesis, or not. They all received 600mg/m2 of CPA combined with either of anthracycline or docetaxel. Their ages were to be less than 65 years, and their GFR's were more than 60 ml/min/1.73m2. Their prior electrolytes were to be within normal range. In the first cycle, we evaluated serum Na levels before the CPA start and that at 24 hours after. We defined serum Na level lower than 135 mEq/L as “hyponatremia” based on previous study. We enrolled 81 patients, in whom 52 were given AP and 29 were without AP, between December 2010 and April 2012. Results The background between the two groups, with AP and without AP, were comparable, in whom the median ages were 53.0(33-64) and 53.2(38-65), and the prior Na levels were139.84 ± 1.89 mEq/L, and 140.25 ± 1.82 mEq/L, in the AP-group and in non-AP-group, respectively. The uses of 5HT3 and DEX were similar between the two groups. The incidence of CPA-induced hyponatremia was significantly higher in AP-group than in non-AP-group (26.9% v 6.9%; P =0.04). The average Na level at 24 hours after chemotherapy was 136.32 ± 3.73 mEq/L in AP-group, and 138.60 ± 2.92 mEq/L in non-AP-group. Among 14 patients who developed hyponateremia in AP-group, they were resolved without any intervention in 13, and one needed Na replacement. The patient did not develop hyponatremia without AP in the third cycle. Conclusions According to our cohort study, AP cause hyponatremia more frequently in the CPA-combined chemotherapy. Disclosure All authors have declared no conflicts of interest." @default.
• W3000049216 created "2020-01-23" @default.
• W3000049216 creator A5005779497 @default.
• W3000049216 creator A5027545625 @default.
• W3000049216 creator A5043208169 @default.
• W3000049216 creator A5046247242 @default.
• W3000049216 creator A5053168111 @default.
• W3000049216 creator A5053550345 @default.
• W3000049216 creator A5060072613 @default.
• W3000049216 creator A5079510779 @default.
• W3000049216 date "2012-09-01" @default.
• W3000049216 modified "2023-09-28" @default.
• W3000049216 title "Correlation between Cyclophosphamide-Induced Hyponatraemia and the Use of Aprepitant" @default.
• W3000049216 doi "https://doi.org/10.1016/s0923-7534(20)34124-7" @default.
• W3000049216 hasPublicationYear "2012" @default.
• W3000049216 type Work @default.
• W3000049216 sameAs 3000049216 @default.
• W3000049216 citedByCount "1" @default.
• W3000049216 countsByYear W30000492162015 @default.
• W3000049216 crossrefType "journal-article" @default.
• W3000049216 hasAuthorship W3000049216A5005779497 @default.
• W3000049216 hasAuthorship W3000049216A5027545625 @default.
• W3000049216 hasAuthorship W3000049216A5043208169 @default.
• W3000049216 hasAuthorship W3000049216A5046247242 @default.
• W3000049216 hasAuthorship W3000049216A5053168111 @default.
• W3000049216 hasAuthorship W3000049216A5053550345 @default.
• W3000049216 hasAuthorship W3000049216A5060072613 @default.
• W3000049216 hasAuthorship W3000049216A5079510779 @default.
• W3000049216 hasBestOaLocation W30000492161 @default.
• W3000049216 hasConcept C121608353 @default.
• W3000049216 hasConcept C126322002 @default.
• W3000049216 hasConcept C134018914 @default.
• W3000049216 hasConcept C2776085618 @default.
• W3000049216 hasConcept C2776694085 @default.
• W3000049216 hasConcept C2776703092 @default.
• W3000049216 hasConcept C2776755627 @default.
• W3000049216 hasConcept C2777170512 @default.
• W3000049216 hasConcept C2780574406 @default.
• W3000049216 hasConcept C2780852908 @default.
• W3000049216 hasConcept C2780884295 @default.
• W3000049216 hasConcept C2781190966 @default.
• W3000049216 hasConcept C530470458 @default.
• W3000049216 hasConcept C71924100 @default.
• W3000049216 hasConcept C90924648 @default.
• W3000049216 hasConcept C98274493 @default.
• W3000049216 hasConceptScore W3000049216C121608353 @default.
• W3000049216 hasConceptScore W3000049216C126322002 @default.
• W3000049216 hasConceptScore W3000049216C134018914 @default.
• W3000049216 hasConceptScore W3000049216C2776085618 @default.
• W3000049216 hasConceptScore W3000049216C2776694085 @default.
• W3000049216 hasConceptScore W3000049216C2776703092 @default.
• W3000049216 hasConceptScore W3000049216C2776755627 @default.
• W3000049216 hasConceptScore W3000049216C2777170512 @default.
• W3000049216 hasConceptScore W3000049216C2780574406 @default.
• W3000049216 hasConceptScore W3000049216C2780852908 @default.
• W3000049216 hasConceptScore W3000049216C2780884295 @default.
• W3000049216 hasConceptScore W3000049216C2781190966 @default.
• W3000049216 hasConceptScore W3000049216C530470458 @default.
• W3000049216 hasConceptScore W3000049216C71924100 @default.
• W3000049216 hasConceptScore W3000049216C90924648 @default.
• W3000049216 hasConceptScore W3000049216C98274493 @default.
• W3000049216 hasLocation W30000492161 @default.
• W3000049216 hasOpenAccess W3000049216 @default.
• W3000049216 hasPrimaryLocation W30000492161 @default.
• W3000049216 hasRelatedWork W1964889552 @default.
• W3000049216 hasRelatedWork W1981712413 @default.
• W3000049216 hasRelatedWork W2002950840 @default.
• W3000049216 hasRelatedWork W2036840908 @default.
• W3000049216 hasRelatedWork W2066107056 @default.
• W3000049216 hasRelatedWork W2304663376 @default.
• W3000049216 hasRelatedWork W2349409747 @default.
• W3000049216 hasRelatedWork W2376781926 @default.
• W3000049216 hasRelatedWork W2427519232 @default.
• W3000049216 hasRelatedWork W2432835554 @default.
• W3000049216 hasRelatedWork W2550875060 @default.
• W3000049216 hasRelatedWork W2838978934 @default.
• W3000049216 hasRelatedWork W2940920071 @default.
• W3000049216 hasRelatedWork W3000334375 @default.
• W3000049216 hasRelatedWork W3031421403 @default.
• W3000049216 hasRelatedWork W3031941719 @default.
• W3000049216 hasRelatedWork W3035746346 @default.
• W3000049216 hasRelatedWork W3146961473 @default.
• W3000049216 hasRelatedWork W3203460494 @default.
• W3000049216 hasRelatedWork W2182391426 @default.
• W3000049216 isParatext "false" @default.
• W3000049216 isRetracted "false" @default.
• W3000049216 magId "3000049216" @default.
• W3000049216 workType "article" @default.